0001209191-20-060047.txt : 20201123
0001209191-20-060047.hdr.sgml : 20201123
20201123175854
ACCESSION NUMBER: 0001209191-20-060047
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201119
FILED AS OF DATE: 20201123
DATE AS OF CHANGE: 20201123
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Bradshaw Curt
CENTRAL INDEX KEY: 0001794633
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38042
FILM NUMBER: 201339309
MAIL ADDRESS:
STREET 1: 177 E COLORADO BLVD
STREET 2: STE 700
CITY: PASADENA
STATE: CA
ZIP: 91105
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ARROWHEAD PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0000879407
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 460408024
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0930
BUSINESS ADDRESS:
STREET 1: 177 E COLORADO BLVD
STREET 2: SUITE 700
CITY: PASADENA
STATE: CA
ZIP: 91105
BUSINESS PHONE: 626-696-4702
MAIL ADDRESS:
STREET 1: 177 E COLORADO BLVD
STREET 2: SUITE 700
CITY: PASADENA
STATE: CA
ZIP: 91105
FORMER COMPANY:
FORMER CONFORMED NAME: ARROWHEAD RESEARCH CORP
DATE OF NAME CHANGE: 20040112
FORMER COMPANY:
FORMER CONFORMED NAME: INTERACTIVE GROUP INC
DATE OF NAME CHANGE: 20020509
FORMER COMPANY:
FORMER CONFORMED NAME: INTERACTIVE INC
DATE OF NAME CHANGE: 19940224
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-11-19
1
0000879407
ARROWHEAD PHARMACEUTICALS, INC.
ARWR
0001794633
Bradshaw Curt
177 E. COLORADO BLVD
SUITE 700
PASADENA
CA
91105
0
1
0
0
Chief Scientific Officer
Common Stock
2020-11-19
4
S
0
15625
69.39
D
15625
D
Common Stock
2020-11-20
4
S
0
15625
68.73
D
0
D
Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities
Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock
units.
The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.16 to $69.06, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
93,750 restricted stock units previously reported have been removed from this amount of securities beneficially owned due to forfeiture.
/s/Curt Bradshaw
2020-11-23